Table 5.
Global disease modifying therapy dates of approval.
| DMT | FDA | EMA | Canada | Australia |
|---|---|---|---|---|
| Interferons AOMS | 1995, 2002, 2009, 2012, 2013, 2014 (pegylated) | 1995 | 1995 | 1996 |
| 1997 | ||||
| 1998 | ||||
| 2008 | ||||
| 2014 | ||||
| Interferons POMS | Age 12–adult | |||
| Glatiramer Acetate AOMS | 1996, 2014 | 2002 | 1997 | 1997 |
| 2015 | ||||
| Glatiramer Acetate POMS | Age 12–adult | |||
| Fingolimod AOMS | 2010 | 2010 | 2011 | 2011 |
| Fingolimod POMS | 2018 Age 10–17 |
2018 Age 10–17 |
||
| Siponimod AOMS | 2019 | |||
| Siponimod POMS | none | |||
| Daclizumab AOMS | 2016, removed from market 2018 | 2016 | xx | xx |
| Teriflunomide AOMS | 2012 | 2013 | 2013 | 2016 |
| Teriflunomide POMS | none | |||
| Dimethyl fumarate AOMS | 2013 | 2014 | 2013 | 2017 |
| Dimethyl fumarate POMS | none | |||
| Cladribine AOMS | 2019 | 2017 | 2017 | 2010, removed from market 2011 |
| Reapproved 2019 | ||||
| Cladribine POMS | none | |||
| Natalizumab AOMS | 2004, returned to market in 2006 | 2006, 2011 SC | 2006 | 2006 |
| Natalizumab POMS | none | |||
| Alemtuzumab AOMS | 2014 | 2013 | 2013 | 2015 |
| reserved for those with inadequate | ||||
| responses to 2 or more MS medications | ||||
| Alemtuzumab POMS | none | |||
| Ocrelizumab AOMS | 2017 | 2018 | 2017 | 2017 |
| RRMS | RRMS | |||
| PPMS | PPMS | |||
| Ocrelizumab POMS | none |
Abbreviations: SC—second line, RRMS—relapsing remitting MS, PPMS—primary progressive MS, AOMS—adult onset Multiple Sclerosis, POMS—pediatric onset multiple sclerosis.